

## December 2020 Gordon Dunn Report

1. CT-based assessment of body composition following neoadjuvant chemo-hormonal therapy in patients with castration-naïve oligometastatic prostate cancer:

<https://pubmed.ncbi.nlm.nih.gov/33259087/>

2. Validation of a prostate cancer polygenic risk score:

<https://pubmed.ncbi.nlm.nih.gov/33258481/>

3. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer:

<https://pubmed.ncbi.nlm.nih.gov/33258507/>

4. Impact of radiation dose on recurrence in high-risk prostate cancer patients:

<https://pubmed.ncbi.nlm.nih.gov/33258482/>